Volta

The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection

Unknown authors · 2023
hash_id: 6111b9761cf143ffbdb4239e839ea60230b34d417a06f3e386a79a7cfaf97988 · DOI: 10.1080/21645515.2023.2236538

To evaluated the risk ratio of Allergic rhinitis (AR) people on the symptoms after COVID-19 infection, and explored the relationship between AR and the symptoms after COVID-19 infection. An observational study was performed of people from outpatient department of the Hospital of Chengdu University of Chinese Medicine. Participants completed an electronic survey and between January 10 to January 20, 2023. We divided the participants into three groups according to the disease information of the population: non-AR people group (AR-N), AR patients with sublingual immunotherapy group (AR-S), and AR patients with conventional therapy group (AR-C). A total of 1116 participants were included in the study, with an average age of 21.76 ± 8.713, women accounted for 62.5%, men accounted for 37.5%. …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary